Loader

Pathways

PathWhiz ID Pathway Meta Data

PW144600

Pw144600 View Pathway
drug action

Rimantadine Drug Metabolism Action Pathway

Homo sapiens

PW146528

Pw146528 View Pathway
drug action

Rimegepant Drug Metabolism Action Pathway

Homo sapiens

PW127841

Pw127841 View Pathway
drug action

Rimexolone Action Pathway

Homo sapiens
Rimexolone, also known as Vexol, is a glucocorticoid used to treat inflammation of the eye. It is available as a 1% eye drop solution. Rimexolone is a glucocorticoid receptor agonist. As this drug is a glucocorticoid, its mechanism of action is that of the glucocorticoid response element (GRE) of influencing COX-2/prostaglandin G/H synthase 2 suppression and lipocortin/annexin induction. By binding to the glucocorticoid receptor, it influences transcription factors AP-1 and NF-kB to block the transcription of COX-2/prostaglandin G/H synthase 2 which reduces the amount of prostanoids being produced from arachidonic acid. Prostanoids such as PGI2 and thromboxane A2 influence the effects of inflammation through vasoconstriction/dilation, pain sensitivity, and platelet aggregation. Rimexolone also affects the promoter of annexin-1, an important inflammatory protein as it affects leukocytes and blocks phospholipase A2 which reduces the amount of arachidonic acid being cleaved from the phospholipid bilayer. Reducing the amount of arachidonic acid formed further decreases the concentrations of prostanoids mentioned calming inflammation.

PW144998

Pw144998 View Pathway
drug action

Rimexolone Drug Metabolism Action Pathway

Homo sapiens

PW132449

Pw132449 View Pathway
metabolic

Rimonabant Drug Metabolism

Homo sapiens
Rimonabant is a drug that is not metabolized by the human body as determined by current research and biotransformer analysis. Rimonabant passes through the liver and is then excreted from the body mainly through the kidney.

PW145667

Pw145667 View Pathway
drug action

Rimonabant Drug Metabolism Action Pathway

Homo sapiens

PW145893

Pw145893 View Pathway
drug action

Riociguat Drug Metabolism Action Pathway

Homo sapiens

PW128527

Pw128527 View Pathway
drug action

Ripretinib Action Pathway

Homo sapiens
Ripretinib is a kinase inhibitor primarily used to treat advanced gastrointestinal stromal tumor (GIST) that has not responded well to other kinase inhibitors like sunitinib and imatinib. Marketed under the name Qinlock, this medication is manufactured by Deciphera Pharmaceuticals and received FDA approval on May 15, 2020. It is notable for being the first drug approved as a fourth-line therapy, specifically for patients who have previously undergone treatment with at least three other kinase inhibitors, including imatinib. Ripretinib's mechanism of action involves inhibiting protein kinases, including both wild type and mutant forms of platelet-derived growth factor receptor A (PDGFRA) and KIT, which are implicated in the majority of gastrointestinal stromal tumors (GIST). This medication has been shown to inhibit other genes like PDGFRB, BRAF, VEGF, and TIE2 in laboratory studies. Its unique dual mechanism involves binding to the kinase switch pocket as well as the activation loop, effectively turning off the kinase and halting its ability to promote uncontrolled cell growth.

PW146893

Pw146893 View Pathway
drug action

Ripretinib Drug Metabolism Action Pathway

Homo sapiens

PW176402

Pw176402 View Pathway
metabolic

Ripretinib Predicted Metabolism Pathway

Homo sapiens
Metabolites of Ripretinib are predicted with biotransformer.